Generic drugmakers continue to face mounting pressure not only from pricing competition but also from Trump’s push for pharmaceutical import tariffs and the proposed “most-favored-nation” pricing ...

Patent settlements accelerate the entry of generics and biosimilars, saving the health care system $422.9 billion and ...

Goldman Sachs initiated coverage on U.S.-listed generic pharmaceutical companies with Buy ratings on Teva Pharmaceutical Industries (NYSE:TEVA) and Amneal Pharmaceuticals (NASDAQ:AMRX), and a Neutral ...